Frozen Shoulder Treatment with Intra-Articular Corticosteroid Injection and Suprascapular Nerve Block

Launched by UNIVERSITAIR ZIEKENHUIS BRUSSEL · Jan 25, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at a new way to treat frozen shoulder, also known as adhesive capsulitis, which causes pain and stiffness in the shoulder and can make everyday activities difficult. The study aims to compare two different treatments: one group will receive a combination of a corticosteroid injection directly into the shoulder joint and a nerve block to help relieve pain, while another group will receive the same injection but with a placebo nerve block (which does not provide pain relief). Researchers want to see which treatment is more effective in reducing pain and improving shoulder movement.

To participate in this study, you must be at least 18 years old, speak Dutch or French, and have been experiencing frozen shoulder symptoms for more than a month. However, there are some exclusions, such as having a history of shoulder trauma or certain medical conditions. If you join the trial, you will receive treatment and be monitored for your shoulder pain, stiffness, and overall ability to do daily activities. This is an important study because it could help identify the best treatment options for people suffering from frozen shoulder.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Written informed consent to participate in the study must be obtained from the subject prior to initiation of any study-mandated procedure
• • Suffering from Frozen Shoulder, defined as: Frozen shoulder is a self-limiting disease characterized by pain and functional restriction in both active and passive shoulder motion lasting more than 1 month, for which radiographic findings of the shoulder joint are unremarkable.
• • Dutch or French speaking persons
• • Age ≥ 18 years
• Exclusion Criteria:
• • Subjects with posttraumatic or postsurgical stiff shoulder syndrome
• • History of trauma at the onset of symptoms
• • Subjects with rheumatologic or neurologic disease involving the shoulder
• • Subjects with cervical radiculopathy
• • Coagulation disorder
• • Hypersensitivity to local anesthetics or MRI contrast agent
• • Inability to understand the study procedures
• • Psychiatric illness
• • Pregnancy
• • Subjects who have received prior SSNB in the homolateral shoulder
• • Subjects who have received an IACI in the homolateral shoulder in the 3 months before inclusion• Systematic yeast infections
• • Hypovolaemia
• • Infections at the injection site
• • Medical history of malignant hyperthermia, major conduction disorders, acute cardiac decompensation, shock conditions, convulsions
• • Control subjects for the diagnostic accuracy part of the study protocol
• * Inclusion criteria:
• • Written informed consent to participate in the study must be obtained from the sub-ject prior to initiation of any study-mandated procedure
• • Subjects suffering from shoulder pain that do not fulfill the diagnostic criteria of Frozen Shoulder
• • Dutch or French speaking persons
• • Age ≥ 18 years
• • Contralateral shoulder of Frozen Shoulder subjects
• • Exclusion criteria
• • Subjects with posttraumatic or postsurgical stiff shoulder syndrome
• • History of trauma at the onset of symptoms
• • Subjects with rheumatologic or neurologic disease involving the shoulder
• • Subjects with cervical radiculopathy
• • Coagulation disorder or treatments with anticoagulants
• • Hypersensitivity to MRI contrast agent
• • Inability to understand the study procedures
• • Psychiatric illness
• • Pregnancy
• • Systematic yeast infections
• • Hypovolaemia
• • Infections at the injection site
• • Medical history of malignant hyperthermia, major conductin disorders, acute cardi-ac decompensation, shock conditions, convulsions